Phase 1 N=3 Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
Brain Neoplasms, Primary Malignant
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=58 Functional Monitoring for Motor Pathway in Brain Tumor Surgery Within Eloquent Area
Glioma, Motor Pathway
Primary: Extent of Tumor Resection — 40; 7; 7; 4 participants
Phase 2 N=336 Indocyanine Green for Central Nervous System Tumors
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
N/A N=12 MRI for Non-invasive Evaluation of Brain Stress
Craniosynostosis
Primary: Blood Flow and Perfusion — 26.8 ml/min/100g — p=0.004
N/A N=12 PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
Glioblastoma Multiforme · Brain Metastases
Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV
N/A N=38 An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
Central Nervous System Neoplasm · Glioma · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio
Phase 1 N=15 [F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
Cancer · Brain Tumors
Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability
N/A N=52 MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
Phase 2 N=8 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Cancer · Brain Cancer · Meningioma
Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…
N/A N=15 Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
Malignant Solid Neoplasm
Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05
Phase 2 N=42 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: Progression-free Survival at 6 Months — 23 Percentage of participants
Early Phase 1 N=6 Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
Blood Brain Barrier Defect
Primary: Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion — 19.1; 18.0 percentage of AUC
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
N/A N=58 Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery
Glioma
Primary: Extent of Resection — 24; 25 participants
Phase 2 N=10 Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection
Brain Tumors With Ill-defined Margins
Primary: Extent of Resection — 97.1 percentage of tumor resected
N/A N=5 Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension
Intracranial Hypotension
Primary: Intracranial Pressure Measurements Estimated by the MRICP Technique. — 6.5 cm H20
Phase 2 N=64 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Adult Anaplastic Oligodendroglioma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…
Phase 1 N=13 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
N/A N=11 Image-Guided Stereotactic Biopsy of High Grade Gliomas
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Phase 1 N=26 Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
N/A N=155 Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
Central Nervous System Lymphoma · Malignant Glioma · Metastatic Malignant Neoplasm in the Brain
Primary: Utility of Femumoxytol and Gadolinium Based Contrast Agents for Improved Imaging Biomarkers of Malignant Brain Tumors in a Single Session by Comparing Dynamic Contrast…
N/A N=15 Radiosurgery and Avastin for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Phase 2 N=83 Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
Glioma · Medulloblastoma
Primary: Percentage of Participants With Objective Response of Complete Response or Partial Response — 32.6; 0 percentage of participants
Phase 2 N=50 FLT-PET Imaging of Brain Tumors in Children
Brain Neoplasms
Primary: [18F] Fluorothymidine ([18F]-FLT) Uptake as a Marker of Cellular Proliferation — 1.57; 3.00 SUV max — p=< 0.001
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
N/A N=180 Detecting Traumatic Intracranial Hemorrhage With the InfraScanner 2500™ in Uganda
Head Trauma · Crushing Skull Injury · Head Injury
Primary: Infrascanner 2500™ Diagnostic Performance — 79; 65; 27; 9 Participants
Phase 4 N=8 Perampanel in Seizure Patients With Primary Glial Brain Tumors
Brain Tumor, Primary
Primary: Percentage of Patients With ≥50% Seizure Reduction During the Maintenance Period Compared With Seizure Frequency Before Initiation of Perampanel
Phase 2 N=25 PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors
Brain Tumor
Primary: Number of Patients Assessed for Toxicity According to CTC Version 3.0 — 25 participants
N/A N=13 [18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
Brain Cancer · Gliomas
Primary: Determine & Comp Biodistribution, Clearance, & Dosimetry of [18F]FACBC & [18F]FLT Tissue/Organs w/i the Field of View of the Dynamic PET Imag Studies prior-to & During…
N/A N=12 Using a Head and Neck Maskless Immobilization Device For Patients With Intracranial Tumors
Brain and Nervous System · Intracranial Neoplasm · Head and Neck Cancer
Primary: Accuracy Measured by Quantifying the Difference in Translational Shifts From the Daily Setup to Planning CT Scan Digitally Reconstructed Radiograph — 0.08; 0.16; -0.02…